Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

McGill University

$26,000.00

The role of CCN5 protein in maintaining normal growth of pancreatic islets

EF 2018-19

Résumé
My previous discovery grant in 2007-2012 was on insulin-like growth factor (IGF)-I, which we and others using conditional knockouts have established as essential for embryonic development, postnatal growth, and maturation of major organ systems. Within the pancreatic islets, it promotes -cell proliferation and survival. In order to explore novel targets of its action, we performed a whole-genome cDNA microarray analysis on isolated islets from mice overexpressing IGF-I, and found 82 genes specifically up- or down-regulated. Prominent amongst which was CCN5/WISP2, previously not known to be either expressed in the pancreatic -cells or induced by IGF-I. CCN or WISP represents a family of six cysteine-rich, glycosylated proteins known to be involved in cell adhesion and extracellular matrix (ECM) remodeling, and cell proliferation. Another isoform, CCN2/CTGF, has already been established to play an essential role in the embryonic development of pancreatic islets. On the other hand, ectopic expression of Wnt1 dramatically induces CCN5 expression, supporting a co-regulation by both Wnt1 and IGF-I on the control of -cell proliferation and survival through CCN5 production.*In order to assess the function of CCN5, we showed that its overexpression and treatment using recombinant protein (rCCN5) accelerated the proliferation of murine insulinoma cells, at least in part by activating Akt kinase and cyclin D1. We thus hypothesize that increased CCN5 production promotes -cell proliferation and regeneration. To further characterize its pro-islet properties, we propose to 1) establish in vitro stimulation of CCN5 on the proliferation of the pancreatic islets. Freshly isolated murine islets will be stimulated by rCCN5, IGF-I or vehicle; cell proliferation will be measured by MTT assay, BrdU or EdU incorporation; and supported by Akt and Erk1/2 phosphorylation, as well as the increases in cyclin D1 and CDK4 levels; 2) establish -cell specific CCN5 gene deletion and assess possible decreases in -cell mass, -cell proliferation and changes in insulin secretion and glucose homeostasis; and 3) characterize a putative cell surface receptor, ChrnA3, identified through TriCEPS-based ligand-receptor capture.*Findings from this proposal will significantly contribute to uncover CCN5 as a novel physiological regulator of pancreatic -cell proliferation, a cell surface receptor and intracellular signaling pathways mediating its actions, in the next 5 yr. In the meantime, we have also been supported by CIHR and Canadian Diabetes Association on the anti-diabetic properties of Reg family proteins. With renewed funding expected from NSERC and CIHR, my longer-term goal is to characterize the biological roles of novel growth factors that our body use to control normal glucose homeostasis and develop pharmaceutical interventions in order to prevent or cure diabetes mellitus.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
RGPIN-2017-05246
Name nom
Liu, JunLi
Department département
Medicine
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2017
Award amount
26000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5111
Research subject group en
Cell biology
Research subject group fr
Biologie cellulaire
Research subject en
Signal transduction
Research subject fr
Transduction de signal
Partie
2
Nb partie
5
Application title
The role of CCN5 protein in maintaining normal growth of pancreatic islets
Keyword
NSERC
Application summary
My previous discovery grant in 2007-2012 was on insulin-like growth factor (IGF)-I, which we and others using conditional knockouts have established as essential for embryonic development, postnatal growth, and maturation of major organ systems. Within the pancreatic islets, it promotes -cell proliferation and survival. In order to explore novel targets of its action, we performed a whole-genome cDNA microarray analysis on isolated islets from mice overexpressing IGF-I, and found 82 genes specifically up- or down-regulated. Prominent amongst which was CCN5/WISP2, previously not known to be either expressed in the pancreatic -cells or induced by IGF-I. CCN or WISP represents a family of six cysteine-rich, glycosylated proteins known to be involved in cell adhesion and extracellular matrix (ECM) remodeling, and cell proliferation. Another isoform, CCN2/CTGF, has already been established to play an essential role in the embryonic development of pancreatic islets. On the other hand, ectopic expression of Wnt1 dramatically induces CCN5 expression, supporting a co-regulation by both Wnt1 and IGF-I on the control of -cell proliferation and survival through CCN5 production.*In order to assess the function of CCN5, we showed that its overexpression and treatment using recombinant protein (rCCN5) accelerated the proliferation of murine insulinoma cells, at least in part by activating Akt kinase and cyclin D1. We thus hypothesize that increased CCN5 production promotes -cell proliferation and regeneration. To further characterize its pro-islet properties, we propose to 1) establish in vitro stimulation of CCN5 on the proliferation of the pancreatic islets. Freshly isolated murine islets will be stimulated by rCCN5, IGF-I or vehicle; cell proliferation will be measured by MTT assay, BrdU or EdU incorporation; and supported by Akt and Erk1/2 phosphorylation, as well as the increases in cyclin D1 and CDK4 levels; 2) establish -cell specific CCN5 gene deletion and assess possible decreases in -cell mass, -cell proliferation and changes in insulin secretion and glucose homeostasis; and 3) characterize a putative cell surface receptor, ChrnA3, identified through TriCEPS-based ligand-receptor capture.*Findings from this proposal will significantly contribute to uncover CCN5 as a novel physiological regulator of pancreatic -cell proliferation, a cell surface receptor and intracellular signaling pathways mediating its actions, in the next 5 yr. In the meantime, we have also been supported by CIHR and Canadian Diabetes Association on the anti-diabetic properties of Reg family proteins. With renewed funding expected from NSERC and CIHR, my longer-term goal is to characterize the biological roles of novel growth factors that our body use to control normal glucose homeostasis and develop pharmaceutical interventions in order to prevent or cure diabetes mellitus.